No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.5x · 10Y median 3.1x · 15th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:06:43.074Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:06:43.074Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:06:43.074Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:06:43.074Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:06:43.074Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:06:43.074Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:06:43.074Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:06:43.074Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for GoodRx Holdings, Inc. (GDRX) stock was $3.35 as of Oct 6, 2026, 10:05 AM EDT, down 0.45% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -25.7% · 3-year avg -13.0%/yr · 5-year avg -40.0%/yr
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications.
Medical - Healthcare Information Services · Santa Monica, CA
LATEST PRICE
$3.35
52-WEEK RANGE
$1.77 - $5.81
BETA
1.60
% FROM 52W HIGH
-42.43%
MARKET CAP
$1.16B
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
78.71
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
1.79
P/S RATIO
TTM
1.48
P/OCF RATIO
TTM
5.75
EV/EBITDA
TTM
8.29
DEBT / EQUITY
0.83
REVENUE TTM
$785.23M
GROSS MARGIN TTM
88.05%
NET PROFIT MARGIN TTM
2.07%
REVENUE GROWTH TTM
TTM vs prior TTM
-1.83%
REVENUE CAGR 3Y
+1.76%
REVENUE CAGR 5Y
+4.47%
TTM TOTAL RETURN
-25.72%
3Y TOTAL RETURN
annualized (CAGR)
-12.98%
5Y TOTAL RETURN
annualized (CAGR)
-39.98%
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
0.08
Revenue Est.
$202.12M
Last Quarter Results
EPS
$0.08
vs Estimate
$0.08
Revenue
$200.41M
vs Estimate
$193.23M
Consensus Rating
Based on 12 analysts
Average Price Target
$3.95
+18.1% upside
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.07 | $0.08 | $0.09 | 7 |
| Quarter ending Dec 2026 | $0.07 | $0.08 | $0.10 | 7 |
| Quarter ending Mar 2027 | $0.08 | $0.09 | $0.09 | 2 |
| Quarter ending Jun 2027 |
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GDRX | $1.16B | $3.35 | -0.45% | -25.72% | -39.98% | N/A | N/A |
| 2AVLN | $1.16B | $26.25 | -2.87% | N/A | N/A | N/A | vs GDRX |
| 3HROW | $1.14B | $30.55 | -0.10% | -32.56% | +27.66% | +23.49% | vs GDRX |
| 4CSTL | $1.12B | $36.62 | -0.10% | +60.94% | -10.28% | N/A | vs GDRX |
| 5BCAX | $1.11B | $16.97 | -1.85% | -4.12% | N/A | N/A | vs GDRX |
| 6AMPH | $1.11B | $25.25 | -0.45% | -5.13% | +6.13% | +2.47% | vs GDRX |
Low
$2.65
Current
$3.35
High
$5.00
| $0.09 |
| $0.09 |
| $0.10 |
| 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.29 | $0.30 | $0.33 | 8 |
| FY 2027 | $0.31 | $0.35 | $0.44 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $198.70M | $202.12M | $204.57M | 8 |
| Quarter ending Dec 2026 | $197.24M | $201.81M | $205.34M | 8 |
| Quarter ending Mar 2027 | $195.30M | $200.08M | $203.45M | 4 |
| Quarter ending Jun 2027 | $202.45M | $207.41M | $210.90M | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $791.05M | $799.65M | $802.82M | 10 |
| FY 2027 | $812.56M | $838.39M | $846.22M | 10 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
